Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques

The latent viral reservoir is the critical barrier for developing an HIV-1 cure. Previous studies have shown that therapeutic vaccination or broadly neutralizing antibody (bNAb) administration, together with a Toll-like receptor 7 (TLR7) agonist, enhanced virologic control or delayed viral rebound,...

Full description

Saved in:

Bibliographic Details
Published in:	Nature communications 2022-06, Vol.13 (1), p.3463-3463, Article 3463
Main Authors:	Walker-Sperling, Victoria E K, Mercado, Noe B, Chandrashekar, Abishek, Borducchi, Erica N, Liu, Jinyan, Nkolola, Joseph P, Lewis, Mark, Murry, Jeffrey P, Yang, Yunling, Geleziunas, Romas, Robb, Merlin L, Michael, Nelson L, Pau, Maria G, Wegmann, Frank, Schuitemaker, Hanneke, Fray, Emily J, Kumar, Mithra R, Siliciano, Janet D, Siliciano, Robert F, Barouch, Dan H
Format:	Article
Language:	eng
Subjects:	Active control Animals Antibodies Antiretroviral agents Antiretroviral therapy Drug therapy HIV HIV Infections - drug therapy HIV-1 Human immunodeficiency virus Immunization Immunization, Passive Macaca mulatta Simian Acquired Immunodeficiency Syndrome Simian Immunodeficiency Virus TLR7 protein Toll-Like Receptor 7 Toll-like receptors Vaccination Vaccines Viral Load
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The latent viral reservoir is the critical barrier for developing an HIV-1 cure. Previous studies have shown that therapeutic vaccination or broadly neutralizing antibody (bNAb) administration, together with a Toll-like receptor 7 (TLR7) agonist, enhanced virologic control or delayed viral rebound, respectively, following discontinuation of antiretroviral therapy (ART) in SIV- or SHIV-infected rhesus macaques. Here we show that the combination of active and passive immunization with vesatolimod may lead to higher rates of post-ART virologic control compared to either approach alone. Therapeutic Ad26/MVA vaccination and PGT121 administration together with TLR7 stimulation with vesatolimod resulted in 70% post-ART virologic control in SHIV-SF162P3-infected rhesus macaques. These data suggest the potential of combining active and passive immunization targeting different immunologic mechanisms as an HIV-1 cure strategy.
ISSN:	2041-1723 2041-1723